Durvalumab and Tremelimumab with Lenvatinib as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma - TREMENDOUS-2

Exclusion Criteria

• -Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Grade ≥2 from previous anticancer therapy.
• -History of hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy.
• -Clinically meaningful ascites.
• -Patients with main portal vein thrombosis.
• -Active or prior documented GI bleeding.
• -Patient currently exhibits symptomatic or uncontrolled hypertension.
• -Patients co-infected with HBV and HCV, or co-infected with HBV and hepatitis D virus (HDV)
• -Uncontrolled intercurrent illness